"Groundbreaking Alzheimer's Drug Offers Hope to Patients Worldwide"

The FDA has expanded the approved use of the drug Leqembi, developed by Eisai and Biogen, to include a wider treatment of Alzheimer's disease. The drug, which reduces amyloid plaques in the brain, has shown to slow symptoms by approximately 30% in medical trials. Israeli physicians and families of patients in the early stages of Alzheimer's are hopeful about the drug's potential, calling on doctors and health maintenance organizations to invest more in early detection. The drug is expected to be available in Israel soon pending approval from the Health Ministry.